Site-specific conjugation of linker drugs to antibodies and resulting ADCs
The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
1. An antibody-drug conjugate compound, comprising an antibody or antigen binding fragment thereof and a linker drug conjugated to said antibody or antigen binding fragment through an engineered cysteine at heavy chain position 41 (according to Kabat numbering) of said antibody or antigen binding fragment; and wherein said antibody-drug conjugate has the formula (I)
wherein said Antibody is the antibody or antigen binding fragment thereof that contains an engineered cysteine at heavy chain position 41,
n is 0, 1, 2, or 3,
m represents an average DAR of from 1 to 6,
R 1 is selected from the group consisting of
y is 1-16, and
R 2 is selected from the group consisting of
2. The compound according to claim 1 , wherein
n is 0 or 1,
m represents an average DAR of from 1.5 to 2,
R 1 is
y is 1-4, and
R 2 is selected from the group consisting of
3. The compound according to claim 2 having the formula (II)
4. The compound according to claim 1 , wherein said antibody binds to an antigen target that is expressed in or on the cell membrane of a tumour cell and wherein said antibody is internalised by the cell after binding to said target, after which the drug is released intracellularly.
5. The compound according to claim 4 , wherein said antibody is an anti-annexin A1 antibody, an anti-CD115 antibody, an anti-CD123 antibody, an anti-CLL-1 antibody, an anti-c-MET antibody, an anti-MUC1 antibody, an anti-PSMA antibody, an anti-5T4 antibody or an anti-TF antibody.
6. The compound according to claim 5 , wherein said antibody is an anti-PSMA monoclonal antibody or an anti-5T4 monoclonal antibody.
7. The compound according to claim 1 , wherein said antibody is an anti-PSMA antibody.
8. The compound according to claim 1 , wherein said antibody is an anti-5T4 antibody.
9. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable excipients.
10. The compound according to claim 7 , wherein the heavy chain of said anti-PSMA antibody comprises the amino acid sequence of SEQ ID NO:2 and the light chain of said anti-PSMA antibody comprises the amino acid sequence of SEQ ID NO:5.
11. The compound according to claim 8 , wherein the heavy chain of said anti-5T4 antibody comprises the amino acid sequence of SEQ ID NO:8 and the light chain of said anti-5T4 antibody comprises the amino acid sequence of SEQ ID NO:11.
12. The pharmaceutical composition according to claim 9 , wherein the composition is in the form of a lyophilized powder or a frozen solution.
13. The pharmaceutical composition of claim 9 , further comprising one or more of a therapeutic antibody or a chemotherapeutic agent, or a combination thereof.
14. The compound according to claim 1 , wherein said antibody or antigen binding fragment further comprises an engineered cysteine at position 375 of the heavy chain (according to Eu numbering) and linker drug is conjugated through said engineered cysteine at position 375.
15. The compound according to claim 1 , wherein said antibody or antigen binding fragment thereof is an IgG antibody or antigen binding fragment thereof.